Your browser doesn't support javascript.
loading
Parkinson's Disease Dementia Patients: Expression of Glia Maturation Factor in the Brain.
Thangavel, Ramasamy; Kaur, Harleen; Dubova, Iuliia; Selvakumar, Govindhasamy Pushphavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P; Govindarajan, Raghav; Kempuraj, Duraisamy.
Afiliação
  • Thangavel R; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Kaur H; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Dubova I; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Selvakumar GP; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Ahmed ME; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Raikwar SP; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Govindarajan R; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Kempuraj D; Department of Neurology, Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
Int J Mol Sci ; 25(2)2024 Jan 18.
Article em En | MEDLINE | ID: mdl-38256254
ABSTRACT
Parkinson's disease (PD) is the second most common progressive neurodegenerative disease characterized by the presence of dopaminergic neuronal loss and motor disorders. PD dementia (PDD) is a cognitive disorder that affects many PD patients. We have previously demonstrated the proinflammatory role of the glia maturation factor (GMF) in neuroinflammation and neurodegeneration in AD, PD, traumatic brain injury (TBI), and experimental autoimmune encephalomyelitis (EAE) in human brains and animal models. The purpose of this study was to investigate the expression of the GMF in the human PDD brain. We analyzed the expression pattern of the GMF protein in conjunction with amyloid plaques (APs) and neurofibrillary tangles (NFTs) in the substantia nigra (SN) and striatum of PDD brains using immunostaining. We detected a large number of GMF-positive glial fibrillary acidic protein (GFAP) reactive astrocytes, especially abundant in areas with degenerating dopaminergic neurons within the SN and striatum in PDD. Additionally, we observed excess levels of GMF in glial cells in the vicinity of APs, and NFTs in the SN and striatum of PDD and non-PDD patients. We found that the majority of GMF-positive immunoreactive glial cells were co-localized with GFAP-reactive astrocytes. Our findings suggest that the GMF may be involved in the pathogenesis of PDD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Doenças Neurodegenerativas / Fator de Maturação da Glia / Demência / Encefalomielite Autoimune Experimental Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Doenças Neurodegenerativas / Fator de Maturação da Glia / Demência / Encefalomielite Autoimune Experimental Idioma: En Ano de publicação: 2024 Tipo de documento: Article